Descriptive Cohort of French Patients Treated with Carbonetherapy Since October 2010 Outside PHRC-ETOILE

Launched by HOSPICES CIVILS DE LYON · Jul 31, 2024

Keywords

ClinConnect Summary

This clinical trial is examining the use of carbonetherapy, a special type of radiation treatment, for patients with certain hard-to-treat cancers that are often difficult to operate on or resistant to traditional radiation. Since October 2010, a group of 53 patients in France has been treated with this therapy outside of a formal study called PHRC-ETOILE. The aim is to understand how well carbonetherapy works for these patients, including its effects on controlling cancer, the quality of life, and any side effects they might experience.

To be eligible for this trial, participants need to be at least 18 years old and have received carbonetherapy for specific types of cancers, such as certain sarcomas and chondrosarcomas, which are rare and challenging to treat. Patients who agree to share their medical data for research and are willing to answer questions about their treatment experience and quality of life can take part. This study will help health authorities assess whether carbonetherapy should be more widely available for patients with similar conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria :
• • Patients aged ≥ 18 years at the time of inclusion
• * Patients treated with Carbonetherapy outside PHRC-ETOILE from October 2010 to December 2023, after validation of their file by the health insurance expert, under an agreement providing for reimbursement for indications similar to those of PHRC-ETOILE for patients unable or unwilling to be included (re-irradiation, rare tumors or tumors of exceptional presentation not included in PHRC-ETOILE inclusion criteria). These include, by way of illustration :
• • Unresectable or non-operable cancers, or those with macroscopically incomplete resection (R2)
• * Radiation-resistant cancers considered eligible according to the following indicative list:
• • Cystic adenoid carcinomas (CAK) of the head and neck (excluding laryngeal and tracheal localizations)
• • Soft-tissue sarcomas
• • Pleiomorphic rhabdomyosarcomas only
• • Retroperitoneal sarcomas subject to technical feasibilitý - movement)
• • Osteosarcomas of any location and any grade
• • Chondrosarcomas (skull base excluded) grade greater than 2
• • Chordomas of the axial skeleton and pelvis (excluding skull base)
• • Angiosarcomas
• • Patients who have not objected to the re-use of medical data for cancer research purposes, and who agree to be contacted by the investigator to complete the quality of life and care pathway questionnaires.
• Exclusion Criteria:
• • Refusal by the living patient to participate in research
• • Failure to carry out initially planned carbon therapy treatment